ClinicalTrials.gg
CompletedNCT06780332PALLADIUMUpdated Oct 1, 2026

Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq

A Phase 4 interventional study of RDD to Palynziq in Phenylketonuria and PKU, sponsored by BioMarin Pharmaceutical. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by BioMarin Pharmaceutical · Phase 4, Interventional, and Treatment

How we know

Updated Oct 1, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 35 studies in Phenylketonurias by BioMarin Pharmaceutical — 3 open to participants now, 5 under way, 1 of them phase 3. Phenylketonurias · BioMarin Pharmaceutical.

Enrollment
25th of 26
9 · median 56
Started
2025
the only one that year
Phase 4
3 of 35
1 open now
Registered
34th of 35
by date

Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the 25th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 4, and was the 34th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

3 of the 35 studies in Phenylketonurias by BioMarin Pharmaceutical are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Phenylketonurias by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

The purpose of this study is to determine if rapid drug desensitization (RDD) to Palynziq will improve drug tolerability and treatment persistence in adult patients on commercial Palynziq experiencing hypersensitivity reactions (HSRs) leading to treatment interruption or reduction of dose or dosing frequency. See Section 10.8 for full list of HSR preferred terms. Study details include:

  • Study duration: Up to 30 weeks (up to 6 weeks for Screening, then RDD, and 24 weeks of follow-up)
  • RDD duration: 1 day
  • Palynziq dosing/follow-up duration: 24 weeks
  • Palynziq dosing frequency: Individualized
Read the detailed description

This is a Phase 4 study to evaluate the impact of RDD on adult (≥18 years old) participants with PKU who have experienced HSRs leading to treatment interruption or reduction of dose or dosing frequency while receiving commercial Palynziq. This is not a blinded study. All participants will undergo the same assessments: Screening, the RDD in clinic on Day 1, in clinic dosing on Day 2, followed by remote visits in weeks 2-24 post-RDD to monitor for HSRs and changes in Palynziq dosing. Remote visits will occur every other week from Week 2 through Week 12, then monthly until Week 24.

The total duration of participation in the trial will be approximately 30 weeks: up to 6 weeks for screening, followed by RDD and 24 weeks of post-RDD follow-up.

No Data Monitoring Committee (DMC) will be used for this trial.

03

Conditions studied

  • Phenylketonuria
  • PKU

Browse trials for

Keywords

  • Phenylketonuria
  • PKU
  • Palynziq
  • pegvaliase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age:

    1.Participants must be 18 years of age or older inclusive, at the time of signing the .

  • Type of Participant and Disease Characteristics 2. Participants must have phenylketonuria and must have been receiving commercial Palynziq and enrolled in the REMS.

    3. Participants must have developed HSRs leading to treatment interruption or reduction of dose or dosing frequency (Graade 2 or above) while on Palynziq, and must be able to undergo RDD within 6weeks from the reactive HSR and last Palynziq dose.

  • Sex and /Barrier Requirement 4. Males and females are eligible to participate in this clinical study. Contraceptive use is not required during the study. Please refer to the Pregnancy section of USPI for further information.
  • Informed Consent 5. Participants must be capable of giving written informed consent as described in Section 10.1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Medical Conditions:

    1. Participant may not have any kind of disorders that, in the opinion of the investigator, may compromise the ability of the participant to give written and/or comply with any aspect of the study, and/or where any aspect of participation would be medically inadvisable for the underlying disorder.
    2. Participant must not be pregnant on the day of the RDD.
    3. Participants with uncontrolled asthma, active upper respiratory infection or other active infections, or cardiovascular disease. Asthma control will be assessed using the Asthma Control Test at screening.
  • Prior/Concomitant Therapies:

    4. Participants were not using antihistamine premedication(s) at the time of reactive HSRs.

    5. Participants are willing and able to resume and tolerate Palynziq at the reactive dose prior to the RDD.

    6. Participant must not be receiving concurrent injectables containing PEG with the exception of PEG-containing vaccines, such as COVID-19 vaccinations (see Section 6.7).

    7.Participants receiving beta blockers.

  • Prior/Concurrent Clinical Study Experience 8. Participants may not be currently participating in an interventional study of any product, device, or procedure, or any other BioMarin clinical trial or post-marketing study.

Other Exclusions 9. Participants must not be experiencing reactions that are not appropriate for RDD, including severe cutaneous adverse reactions (SCAR) as defined by the American Academy for Allergy, Asthma, and Immunology.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    RDD

    Participants undergoing RDD to Palynziq

    Drug: RDD to Palynziq

Interventions

  • DrugRDD to Palynziq

    Delivery of gradually increasing doses of Palynziq at fixed time intervals over the course of several hours to a cumulative dose equal to the reactive dose. Reactive dose is defined as the dose at which the reactive HSR occurred which led to treatment interruption or reduction of dose or dose frequency.

06

What researchers measure

Primary outcomes

  1. To determine if RDD to Palynziq improves drug tolerability and treatment persistence in adults with PKU experiencing HSRs leading to treatment interruption or reduction of dose or dosing frequency (reactive HSR).

    Tolerance, defined as the ability to restart Palynziq at the dose at which the reactive HSR occurred (reactive dose) and escalate as appropriate within 24 weeks following the RDD, without requiring treatment interruption or reduction of dose or dosing frequency due to HSRs and reduction in occurrence of HSRs Grade 2 or above within 24 weeks following RDD

    Time frame: 24 weeks

Secondary outcomes

  1. To characterize the immune response to Palynziq following RDD

    Change in PEG IgG and IgM, PAL IgG and PAL IgM, and C3/C4 from Baseline to after RDD and at Week 24

    Time frame: 24 weeks

07

Study locations

1 site
  • Uncommon Cures
    Chevy Chase, Maryland 20815, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Aug 2026, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Feb 7, 2025
Primary completionActual
Aug 17, 2026
CompletionActual
Aug 17, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06780332
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Feb 7, 2025
Primary completion
Aug 17, 2026
Completion
Aug 17, 2026
Last update
Oct 1, 2026

Study contacts

Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion